Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take aim at Hard-to-Treat autoimmune diseases

NCT ID NCT07144462

Recruiting now Disease control Sponsor: Neukio Biotherapeutics (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental cell therapy called NEUK203-215 in adults aged 18-65 with severe autoimmune diseases like lupus or scleroderma that have not responded to other treatments. The therapy uses immune cells from a healthy donor, engineered to target and attack faulty immune cells. Participants also receive chemotherapy drugs to prepare their bodies for the cell infusion. The study focuses on safety and tolerability, with a small group of 8 people.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a healthy donor allogeneic CD19/BCMA-targeted CAR-NK cell product called NEUK203-215, given with chemotherapy drugs fludarabine and cyclophosphamide
What this could lead to
If successful, this could point toward a new treatment option for people with severe autoimmune diseases that have not responded to standard therapies.
What could go wrong
This is a very early, small trial with only 8 participants, so results may not apply broadly. There are risks of side effects from the cell therapy and chemotherapy, including infections and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune bullous skin disease autoimmune disease diffuse cutaneous systemic sclerosis inclusion body myositis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Changzheng Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200131, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.